Table Summary of findings for the linked evidence comparison of mpMRI, relative to TRUSGB or TPUSGB, in patients at low-concern with suspected prostate cancer with assumed pre-test probability (prevalence) of 35% Outcomes Patients/ Quality of No. per 100 patients with No. per 100 patients with Importance Comments evidencea intervention comparator Studies [95% CI]b [95% CI]c True positives 2,062 patients 26 [20,30] 28 [25, 31] Critical Will undergo biopsy as under current management. ⨁⨁⨀⨀ (10 studies). False positives 2,062 patients 15 [9, 24] 0 [0, 0] Critical Will undergo biopsy as under current management. ⨁⨁⨀⨀ (10 studies). True negatives 2,062 patients 50 [41, 56] 65 [65, 65] Critical Will avoid biopsy adverse events. ⨁⨁⨀⨀ (10 studies). False negatives 2,062 patients 9 [5,15] 7 [4, 11] Critical Will avoid the adverse events of biopsy but possible ⨁⨁⨀⨀ detriment due to delayed treatment. (10 studies). 45,492 Major infection 0 TRUSGB: Range 0-2 Critical - ⨁⨁⨀⨀ patients TPUSGB: 0 (8 studies). Minor infection 132,239 0 TRUSGB: Range 0-7 Critical - ⨁⨁⨀⨀ patients TPUSGB: Range 0-1 (9 studies). Re-hospitalisation 292,956 0 TRUSGB: Range 0-6 Critical - ⨁⨁⨀⨀ patients TPUSGB: Range 1-2 (9 studies) Bleeding 334,688 0 TRUSGB: Range 1-88 Important - ⨁⨀⨀⨀ patients TPUSGB: Range 1-6 (13 studies). Urinary obstruction 132,020 0 TRUSGB: Range 1-21 Important - ⨁⨀⨀⨀ patients TPUSGB: Range 0-38 (12 studies). Overall survival 41,146 NA NA Critical Delay did not impact overall survival (results from 5 ⨁⨀⨀⨀ (5 studies). studies).
Table Summary of findings for the linked evidence comparison of mpMRI, relative to TRUSGB or TPUSGB, in patients at low-concern with suspected prostate cancer with assumed pre-test probability (prevalence) of 35% Outcomes Patients/ Studies Quality of evidencea No. per 100 patients with intervention [95% CI]b No. per 100 patients with comparator [95% CI]c Importance Comments True positives 2,062 patients (10 studies). ⨁⨁⨀⨀ 26 [20,30] 28 [25, 31] Critical Will undergo biopsy as under current management. False positives 2,062 patients (10 studies). ⨁⨁⨀⨀ 15 [9, 24] 0 [0, 0] Critical Will undergo biopsy as under current management. True negatives 2,062 patients (10 studies). ⨁⨁⨀⨀ 50 [41, 56] 65 [65, 65] Critical Will avoid biopsy adverse events. False negatives 2,062 patients (10 studies). ⨁⨁⨀⨀ 9 [5,15] 7 [4, 11] Critical Will avoid the adverse events of biopsy but possible detriment due to delayed treatment. Major infection 45,492 patients (8 studies). ⨁⨁⨀⨀ 0 TRUSGB: Range 0-2 TPUSGB: 0 Critical - Minor infection 132,239 patients (9 studies). ⨁⨁⨀⨀ 0 TRUSGB: Range 0-7 TPUSGB: Range 0-1 Critical - Re-hospitalisation 292,956 patients (9 studies) ⨁⨁⨀⨀ 0 TRUSGB: Range 0-6 TPUSGB: Range 1-2 Critical - Bleeding 334,688 patients (13 studies). ⨁⨀⨀⨀ 0 TRUSGB: Range 1-88 TPUSGB: Range 1-6 Important - Urinary obstruction 132,020 patients (12 studies). ⨁⨀⨀⨀ 0 TRUSGB: Range 1-21 TPUSGB: Range 0-38 Important - Overall survival 41,146 (5 studies). ⨁⨀⨀⨀ NA NA Critical Delay did not impact overall survival (results from 5 studies).
1397_Final_MSAC_Assessment_Report.docx